Chengdu Suncadia Medicine Co., Ltd.
🇨🇳China
Clinical Trials
15
Active:3
Completed:8
Trial Phases
4 Phases
Phase 1:6
Phase 2:4
Phase 3:4
+1 more phases
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (40.0%)Phase 2
4 (26.7%)Phase 3
4 (26.7%)Not Applicable
1 (6.7%)Investigation of Drug-drug Interaction of HRS-5965 With Clopidogrel and Clarithromycin in Healthy Subjects
Not Applicable
Completed
- Conditions
- Complement Mediated Glomerular DiseasesHemolytic Anemia
- Interventions
- First Posted Date
- 2025-06-27
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT07040787
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Healthy Subjects
Phase 1
Completed
- Conditions
- IgA NephropathyParoxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 Capsules
- First Posted Date
- 2025-06-25
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT07035665
- Locations
- 🇨🇳
ZhongShan Hospital FuDan University, Shanghai, Shanghai, China
🇨🇳ZhongShan Hospital FuDan University, Shanghai, Shanghai, China
A Trial of HRS-5965 Capsule in Primary IgA Nephropathy
- First Posted Date
- 2025-06-11
- Last Posted Date
- 2025-08-05
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 378
- Registration Number
- NCT07014826
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment
Phase 3
Active, not recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria
- Interventions
- Drug: HRS-5965 capsule
- First Posted Date
- 2024-12-04
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06715943
- Locations
- 🇨🇳
Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin, Tianjin Municipality, China
🇨🇳Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China
A Safety, Tolerability, Pharmacokinetic/Pharmacodynamic Study, and QT Interval Study of HRS-5965 Capsules in Healthy Subjects
Phase 1
Completed
- Conditions
- Hemolytic Anemia
- Interventions
- Drug: HRS-5965 capsuleDrug: HRS-5965 capsule placebo
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-07-04
- Lead Sponsor
- Chengdu Suncadia Medicine Co., Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT06684041
- Locations
- 🇨🇳
Zhongnan hospital of Wuhan University, Wuhan, Hubei, China
- Prev
- 1
- 2
- 3
- Next
News
No news found